Literature DB >> 32767493

Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis.

Carolina M Perdomo1, Marta García-Goñi1, Lidia Sancho2, José J Paricio3, María D Lozano3, Magdalena de la Higuera1, María Currás1, Javier Arbizu2, Juan C Galofré1,4.   

Abstract

OBJECTIVE: A differential diagnosis of thyrotoxicosis is crucial as the treatment of the main causes of this condition can vary significantly. Recently published diagnostic guidelines on thyrotoxicosis embrace the presence of thyrotropin receptor (TSH-R) antibodies (TRAb) as the primary and most important diagnostic step. The application of diagnostic algorithms to aid in the treatment of hyperthyroidism supports using thyroid radionuclide scintigraphy (TRSt) in baffling clinical scenarios, when TRAb are absent or when third-generation TRAb are not available. First-generation TRAb measurement may have limitations. Consequently, patients with thyrotoxicosis and first-generation TRAb results may be misdiagnosed and consequently improperly treated. Our purpose was to compare first-generation TRAb values to TRSt in the differential diagnosis of hyperthyroidism.
METHODS: We conducted a retrospective study of 201 untreated outpatients with overt or subclinical hyperthyroidism on whom first-generation TRAb and TRSt had been performed at the time of diagnosis. Histological specimens were analysed in patients who had previously undergone thyroid surgery at our centre. SPSS 20.0 was used in statistical analysis.
RESULTS: Seventy-three out of 201 (36.3%) patients had positive TRAb. A diffuse uptake was present in 83.5% (61/73), whereas 13.7% (10/73) had a heterogeneous uptake and 2.7% (2/73) had an absent uptake. Thirty out of 91 (33%) patients with diffuse uptake were negative for positive TRAb and were diagnosed with Graves' disease. Analysis of 37 histological specimens indicated that TRSt had greater accuracy (81% vs 75.7%) and specificity (79.2% vs 57.1%) when compared to TRAb in the differential diagnosis of thyrotoxicosis. However, TRSt sensitivity was inferior to TRAb (84.6% vs 92.3%).
CONCLUSIONS: Our study endorses that initial differential diagnosis of thyrotoxicosis should not be based solely on first-generation TRAb as this approach may leave nearly 20% of the patients misdiagnosed and, consequently, improperly treated. Our results underscore that thyroid scintigraphy should also be performed when only first-generation TRAb assays are available during the initial differential diagnosis of thyrotoxicosis.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  differential diagnosis; hyperthyroidism; thyrotoxicosis

Mesh:

Substances:

Year:  2020        PMID: 32767493     DOI: 10.1111/cen.14308

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  The prevalence and significance of nonuniform thyroid radio-isotope uptake in patients with Graves' disease.

Authors:  Altayeb Abdalaziz; Ramesh Vanka; Peter Bartholomew; Nicholas Vennart; Jonathan Vernazza; Kathryn Stewart; Vasileios Tsatlidis; Kilimangalam Narayanan; Jolanta U Weaver; Salman Razvi
Journal:  Clin Endocrinol (Oxf)       Date:  2022-03-13       Impact factor: 3.523

2.  Subacute Thyroiditis-Still a Diagnostic Challenge: Data from an Observational Study.

Authors:  Taiba Zornitzki; Sorcha Mildiner; Tal Schiller; Alena Kirzhner; Viviana Ostrovsky; Hilla Knobler
Journal:  Int J Environ Res Public Health       Date:  2022-07-31       Impact factor: 4.614

3.  Hyperthyroidism in children and adolescents: Experience in a university hospital in Colombia

Authors:  Judith Sofía García; María Paula Sarmiento; Jesús David Bello; Nora Alejandra Zuluaga; Adriana Carolina Forero; Laura Fernanda Niño
Journal:  Biomedica       Date:  2022-06-01       Impact factor: 1.173

4.  Differential Diagnosis of Thyrotoxicosis by Machine Learning Models with Laboratory Findings.

Authors:  Jinyoung Kim; Han-Sang Baek; Jeonghoon Ha; Mee Kyoung Kim; Hyuk-Sang Kwon; Ki-Ho Song; Dong-Jun Lim; Ki-Hyun Baek
Journal:  Diagnostics (Basel)       Date:  2022-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.